Compare PED & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PED | OABI |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | 25 | 89 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.3M | 237.4M |
| IPO Year | 2012 | N/A |
| Metric | PED | OABI |
|---|---|---|
| Price | $16.11 | $1.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $30.00 | $4.50 |
| AVG Volume (30 Days) | 30.3K | ★ 521.0K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $45,751,000.00 | N/A |
| Revenue This Year | $171.75 | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.67 | N/A |
| 52 Week Low | $0.43 | $1.22 |
| 52 Week High | $18.89 | $2.22 |
| Indicator | PED | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 58.72 | 39.91 |
| Support Level | $14.12 | $1.32 |
| Resistance Level | $18.89 | $1.70 |
| Average True Range (ATR) | 1.04 | 0.09 |
| MACD | -0.48 | 0.01 |
| Stochastic Oscillator | 50.00 | 11.36 |
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties with a long production history, well-defined geology, and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming, the Powder River Basin (PRB) in Wyoming, and the San Andres formation of the Permian Basin situated in West Texas and eastern New Mexico (the Permian Basin).
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.